Adaptimmune to Participate in Two Bank Conferences this September
Rhea-AI Summary
Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company focused on redefining solid tumor cancer treatment with cell therapy, has announced its participation in two major investment bank conferences this September:
1. Wells Fargo Healthcare Conference in Boston, MA on September 4, 2024, at 4:30 PM EDT.
2. H.C. Wainwright 26th Annual Global Investment Conference in NYC, NY on September 9, 2024, at 9:50 AM EDT.
Both events will feature fireside chats and will be webcast live on Adaptimmune's website. Replays will be available for a time after the events.
Positive
- None.
Negative
- None.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in two investment bank conferences this September.
- Wells Fargo Healthcare Conference, Boston, MA
- Fireside chat: Wednesday September 4, 2024, at 4:30 PM EDT.
- H.C. Wainwright 26th Annual Global Investment Conference, NYC, NY
- Fireside chat: Monday September 9, 2024, at 9:50 AM EDT.
The events will be webcast live and can be accessed by visiting 'Events', under the 'News Center' tab, in the 'Investors & Media' section of Adaptimmune's website at www.adaptimmune.com. Following the events, a replay of the presentation will be made available for a limited time.
About Adaptimmune
Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221235
FAQ
When is Adaptimmune (ADAP) participating in the Wells Fargo Healthcare Conference?
What is the date and time for Adaptimmune's (ADAP) fireside chat at the H.C. Wainwright Global Investment Conference?
How can investors access the webcasts of Adaptimmune's (ADAP) conference presentations?
What is the focus of Adaptimmune Therapeutics (ADAP) in cancer treatment?
